GO
Loading...

Allergan Inc

More

  • Bill Ackman: Herbalife is like Bernie Madoff Wednesday, 7 Jan 2015 | 11:26 AM ET
    Bill Ackman appears on CNBC's "Squawk Box" in New York.

    Bill Ackman renewed his attack on Herbalife during a CNBC interview Wednesday, likening the nutrition and weight management company to Bernie Madoff.

  • Cramer's 10 lessons learned from 2014 Monday, 5 Jan 2015 | 6:10 PM ET
    Traders on the floor of the New York Stock Exchange.

    On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.

  • The best hedge funds for 2015 are... Friday, 2 Jan 2015 | 7:00 AM ET
    Ray Dalio, Bridgewater Associates

    Critics love to hate hedge fund fees and performance, but the industry is poised to grow even more in 2015.

  • 3 hedge fund predictions for 2015   Wednesday, 31 Dec 2014 | 10:43 AM ET
    3 hedge fund predictions for 2015

    CNBC's Kate Kelly reveals what investors can expect from hedge funds and activists in 2015.

  • Tax inversion anyone? A year in M&A Monday, 29 Dec 2014 | 1:20 AM ET

    Mergers and acquisitions broke a seven-year losing streak in 2014, with $3.48 trillion worth of deals. CNBC looks at some of the year's highlights.

  • Spain's Almirall gains on report of Actavis interest Friday, 19 Dec 2014 | 12:29 PM ET

    Dec 19- Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis. Almirall played down the report, saying in a regulatory filing that "the news is untrue." Almirall, with a market value of 2.3 billion euros, recently sold its respiratory business to AstraZeneca, while Actavis is in the...

  • Dec 18- Hedge fund Paulson& Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter. The fund has recently taken a number of large positions in healthcare companies, including Shire PLC, where...

  • Dec 16- Salix Pharmaceuticals Ltd said it would clear excess inventory by the end of 2015, a year earlier than it had forecast, sending its shares up about 6 percent premarket. The company forecast a profit of $3.10- $4.10 per share on total net product revenue of $1.25- $1.35 billion for 2015.. Salix also said the U.S. Food and Drug Administration has delayed a...

  • It spent $5.7 billion for the rights to some injectable wrinkle treatments of Valeant Pharmaceuticals and for L'Oreal's share of a dermatology joint venture the two operated. Nestle is also spending about $350 million on dermatology research and development this year, said Humberto Antunes, chief executive of Nestle Skin Care. The first of the new research...

  • Valeant to drop deal-making to cut debt, lift stock Tuesday, 9 Dec 2014 | 9:00 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Early Movers: UTX, LULU, AEO, VZ, AMZN & more Tuesday, 9 Dec 2014 | 7:48 AM ET

    Some of the names on the move ahead of the open.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Ackman's 'animal' spirits alive in latest venture Monday, 1 Dec 2014 | 2:58 PM ET
    Zoetis

    Fresh of a big win from investing in human drugs, Bill Ackman is now focused on pharmaceuticals for animals.

  • BOSTON, Nov 26- Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.. One week after Allergan agreed to sell itself to rival Actavis Plc., Ackman wrote in his quarterly investment letter that his Pershing Square Capital Management, the Botox-maker's biggest...

  • *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures pointed to a higher open on Monday, indicating that major indexes would move further into record territory on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday,...

  • US STOCKS-Futures rise, boosted by merger activity Monday, 24 Nov 2014 | 8:14 AM ET

    *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures rose on Monday, indicating that major indexes would move further into record territory, on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday, with the Dow and S&P...

  • Midday movers: Intel, Toyota, Petrobras & more Friday, 21 Nov 2014 | 12:25 PM ET
    Trader on the floor of the New York Stock Exchange.

    Take a look at some of Friday's midday movers:

  • Goldman Sachs Group Inc retained its No. 1 position as M&A adviser with deals worth $877 billion, followed by JPMorgan Chase& Co with $651 billion and Citigroup Inc with $633 billion. The $66.4 billion bid for Allergan Inc by Actavis PLC this week more than doubled the total value of deals in the healthcare sector to $364 billion. Halliburton Co's plans to buy...

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.